These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 26788733)
1. Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives. Signorelli C; Chiesa V; Odone A J Prev Med Hyg; 2015 Aug; 56(3):E125-32. PubMed ID: 26788733 [TBL] [Abstract][Full Text] [Related]
2. Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme. Tirani M; Meregaglia M; Melegaro A PLoS One; 2015; 10(4):e0123383. PubMed ID: 25874805 [TBL] [Abstract][Full Text] [Related]
3. Clinical experience with the meningococcal B vaccine, Bexsero(®): Prospects for reducing the burden of meningococcal serogroup B disease. Watson PS; Turner DP Vaccine; 2016 Feb; 34(7):875-80. PubMed ID: 26686570 [TBL] [Abstract][Full Text] [Related]
4. Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine - Advisory Committee on Immunization Practices, 2016. Patton ME; Stephens D; Moore K; MacNeil JR MMWR Morb Mortal Wkly Rep; 2017 May; 66(19):509-513. PubMed ID: 28520709 [TBL] [Abstract][Full Text] [Related]
5. Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015. MacNeil JR; Rubin L; Folaranmi T; Ortega-Sanchez IR; Patel M; Martin SW MMWR Morb Mortal Wkly Rep; 2015 Oct; 64(41):1171-6. PubMed ID: 26492381 [TBL] [Abstract][Full Text] [Related]
6. The introduction of the meningococcal B (MenB) vaccine (Bexsero®) into the national infant immunisation programme--New challenges for public health. Ladhani SN; Campbell H; Parikh SR; Saliba V; Borrow R; Ramsay M J Infect; 2015 Dec; 71(6):611-4. PubMed ID: 26433141 [TBL] [Abstract][Full Text] [Related]
7. Exploring the population-level impact of MenB vaccination via modeling: Potential for serogroup replacement. Hogea C; Van Effelterre T; Vyse A Hum Vaccin Immunother; 2016; 12(2):451-66. PubMed ID: 26308796 [TBL] [Abstract][Full Text] [Related]
8. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada. Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732 [TBL] [Abstract][Full Text] [Related]
9. Distribution of invasive meningococcal B disease in Italian pediatric population: implications for vaccination timing. Azzari C; Canessa C; Lippi F; Moriondo M; Indolfi G; Nieddu F; Martini M; de Martino M; Castiglia P; Baldo V; Resti M; Vaccine; 2014 Feb; 32(10):1187-91. PubMed ID: 24120548 [TBL] [Abstract][Full Text] [Related]
10. Invasive bacterial diseases: national surveillance in Italy and vaccination coverage in the Local Health Agency 4 "Chiavarese", Liguria region (Italy). Trucchi C; Zoppi G J Prev Med Hyg; 2012 Jun; 53(2):120-4. PubMed ID: 23240174 [TBL] [Abstract][Full Text] [Related]
11. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy. Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162 [TBL] [Abstract][Full Text] [Related]
12. Acceptability of meningococcal serogroup B vaccine among parents and health care workers in Italy: a survey. Mameli C; Faccini M; Mazzali C; Picca M; Colella G; Duca PG; Zuccotti GV Hum Vaccin Immunother; 2014; 10(10):3004-10. PubMed ID: 25483638 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Parikh SR; Andrews NJ; Beebeejaun K; Campbell H; Ribeiro S; Ward C; White JM; Borrow R; Ramsay ME; Ladhani SN Lancet; 2016 Dec; 388(10061):2775-2782. PubMed ID: 28100432 [TBL] [Abstract][Full Text] [Related]
15. Will booster doses be required for serogroup B meningococcal vaccine? McQuaid F; Snape MD Expert Rev Vaccines; 2014 Mar; 13(3):313-5. PubMed ID: 24451002 [TBL] [Abstract][Full Text] [Related]
16. The Long Road to an Effective Vaccine for Meningococcus Group B (MenB). Shea MW Ann Med Surg (Lond); 2013; 2(2):53-6. PubMed ID: 25628885 [TBL] [Abstract][Full Text] [Related]
17. Safety profile of MenB-FHBp vaccine among adolescents: data from surveillance of Adverse Events Following Immunization in Puglia (Italy), 2018-2020. Stefanizzi P; Bianchi FP; Martinelli A; Di Lorenzo A; De Petro P; Graziano G; Lattanzio S; Diella G; Stella P; Ancona D; Tafuri S Hum Vaccin Immunother; 2022 Dec; 18(1):2041359. PubMed ID: 35201942 [TBL] [Abstract][Full Text] [Related]
18. A combined approach to assess the potential coverage of a multicomponent protein-based vaccine. Boccadifuoco G; Brunelli B; Pizza MG; Giuliani MM J Prev Med Hyg; 2012 Jun; 53(2):56-60. PubMed ID: 23240161 [TBL] [Abstract][Full Text] [Related]
19. Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine. Esposito S; Principi N Expert Rev Vaccines; 2014 Feb; 13(2):193-202. PubMed ID: 24393061 [TBL] [Abstract][Full Text] [Related]
20. Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease. Dull PM; McIntosh ED Vaccine; 2012 May; 30 Suppl 2():B18-25. PubMed ID: 22607895 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]